Latest news
KRRO: Lead RNA editing programs advanced, cash runway into 2028, and net loss narrowed year-over-year - TradingViewTradingView · Thu, 06 Aug 2026 11:14:16 GMTKorro Bio Swaps 1.0M Shares for Pre-Funded Warrants to Venrock at $0.001 Exercise Price - TradingViewTradingView · Thu, 06 Aug 2026 11:13:01 GMTKorro Bio, Inc. Q2 2026: Revenue $0M, Net loss $(18.9)M, EPS $(1.07) — 10-Q Summary - TradingViewTradingView · Thu, 06 Aug 2026 11:11:00 GMTKRRO: Net loss narrowed to $38.5M in H1 2026; cash runway extends into 2H 2028 - TradingViewTradingView · Thu, 06 Aug 2026 11:09:25 GMTKorro Bio, Inc. Revenue Breakdown – NASDAQ:KRRO - TradingViewTradingView · Mon, 27 Jul 2026 09:12:37 GMT